On October 6, Thermo Fisher Scientific declined 3.12% during regular trading, with the stock changing hands at approximately $655.66 per share and turnover surpassing $5.1 billion.

The move came despite Barclays raising its price target on the company to $750 from $650, reiterating an overweight rating, suggesting the decline primarily reflects profit-taking following a strong run-up rather than deteriorating fundamentals.

Supporting the long-term outlook, Thermo Fisher recently entered a study start-up agreement with Quantum BioPharma for a Phase 2 multiple sclerosis trial, expanding its clinical research pipeline. Earlier in the session, the stock had risen as much as 3% before reversing, while peers such as Illumina, Tempus AI, and Danaher traded lower, contributing to broader sector weakness in life sciences tools and services.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)